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Introduction: Bone abnormalities, one of the primary manifestations of Menkes disease (MD), include a weakened
bone matrix and low mineral density. However, the molecular and cellular mechanisms underlying these bone
defects are poorly understood.
Methods: We present in vitro modeling for impaired osteogenesis in MD using human induced pluripotent stem
cells (iPSCs) with a mutated ATP7A gene. MD-iPSC lines were generated from two patients harboring different
mutations.
Results: The MD-iPSCs showed a remarkable retardation in CD105 expression with morphological anomalies
during development to mesenchymal stem cells (MSCs) compared with wild-type (WT)-iPSCs. Interestingly,
although prolonged culture enhanced CD105 expression, mature MD-MSCs presented with low alkaline
phosphatase activity, reduced calcium deposition in the extracellular matrix, and downregulated osteoblast-specific
genes during osteoblast differentiation in vitro. Knockdown of ATP7A also impaired osteogenesis in WT-MSCs. Lysyl
oxidase activity was also decreased in MD-MSCs during osteoblast differentiation.
Conclusions: Our findings indicate that ATP7A dysfunction contributes to retardation in MSC development and impairs
osteogenesis in MD.Introduction
Menkes disease (MD) is a copper metabolism disorder
that is caused by a loss-of-function of a major copper
transporter, ATP7A [1, 2]. The ATP7A gene is located
on the long arm of X chromosome and encodes a P-type
ATPase, which plays crucial roles in cellular copper me-
tabolism by controlling copper export and intracellular
copper trafficking [3, 4]. Although its primary physio-
logical function is copper absorption in the small intes-
tine, ATP7A is also implicated in intracellular copper
delivery to copper-dependent enzymes [5, 6]. A variety
of copper-dependent enzymes become nonfunctional
due to a lack of ATP7A activity in MD patients, which
can lead to multisystemic clinical symptoms [6, 7].
Clinical manifestations of MD patients include pro-
gressive neurodegeneration, connective tissue defects,
sparse and kinky hairs, vascular defects, and many
others. Connective tissue defects comprise tortuous* Correspondence: ymhan57@kaist.ac.kr
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so forth [7–9]. Similarly, MD mouse models present
with fragmentation of the internal elastic lamina, defect-
ive synthesis of bone collagen, reduced skin tensile
strength, and weak blood vessels [10–12]. Among the
various symptoms, bone abnormalities are a typical
phenotype in MD patients [13–15]. Bone abnormalities
in Menkes patients include osteoporosis, metaphyseal
spurs, diaphyseal fractures, and wormian occipital bones
[15–19]. Bone defects have also been shown in occipital
horn syndrome, a mild phenotype of ATP7A-deficient
disease [20]. Defective phenotypes in bone formation are
frequently used as a diagnostic test in the early stage
along with a blood test to measure low serum copper
levels [16]. However, in vitro model systems that investi-
gate how ATP7A mutations result in abnormal bone for-
mation in MD have not been reported. Here, we attempt
to model MD pathogenesis at the cellular level using in-
duced pluripotent stem cells (iPSCs) in vitro. Human
iPSCs, which have the capability to differentiate into
various cell types and to proliferate indefinitely, areis distributed under the terms of the Creative Commons Attribution 4.0
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man diseases [21, 22].
In this study, MD-iPSCs were differentiated into oste-
oblasts (OBs) to investigate the effect of ATP7A dys-
function on bone formation. Intriguingly, MD-iPSCs
showed delayed mesenchymal stem cell (MSC) matur-
ation compared with wild-type (WT)-iPSCs. Subse-
quently, MD-MSCs showed impaired osteogenesis in
terms of alkaline phosphatase (ALP) activity, calcium
mineralization, and transcription of osteogenic genes.
Copper chelation in WT-MSCs resembled defective
phenotypes shown in MD-MSCs. Our results demon-
strate that dysfunction of copper utilization in MD




For retrovirus packaging, retroviral vectors encoding
OCT4, SOX2, KLF4, cMYC (Addgene, Cambridge, MA,
USA) were co-transfected with VSV-G vector (Takara Bio,
Mountain View, CA, USA) in GP2 293 cells. Transfectants
were further incubated in Dulbecco’s modified Eagle’s
medium (DMEM; Welgene, Seoul, Korea) supplemented
with 10 % fetal bovine serum (FBS; Invitrogen, Carlsbad,
CA, USA) and 1 % penicillin-streptomycin (Invitrogen) at
37 °C, 5 % CO2 in air. The medium was changed 8 h after
transfection. Then, supernatants were harvested 48 and
72 h after incubation. Supernatants harvested from four
dishes (10 cm in diameter) per factor were ultracentri-
fuged at 90,000 × g for 90 min at 4 °C. The viral pellet was
dissolved in 2 ml of the medium and kept at −70 °C before
use.
Generation and maintenance of MD-iPSCs
To generate MD-iPSCs, patient fibroblasts were infected
with four retroviruses and then plated onto mitomycin
C-treated (MMC; A.G. Scientific, San Diego, CA, USA)
MEF feeder layers at a density of 103 cells/cm2. This
study using patient fibroblasts was approved by the
Institutional Review Board of Asan Medical Center, and
written informed consent was obtained from their par-
ents. Infected cells were cultured in human embryonic
stem cell (ESC) medium at 37 °C, 5 % CO2 in air for 2 to
3 weeks. The human ESC medium consists of DMEM/
F12 (Invitrogen) supplemented with 20 % Knockout SR
(Invitrogen), 1 % nonessential amino acids (Invitrogen),
1 % penicillin-streptomycin, 0.1 mM β-mercaptoethanol
(Sigma, St. Louis, MO, USA), and 10 ng/ml fibroblast
growth factor (FGF)2 (R&D systems, Minneapolis, MN,
USA). Respective human ESC-like colonies were mechan-
ically transferred onto new MMC-treated MEF feeders
and subcultured for stabilization for 10 to 20 passages.
iPSC characteristics were analyzed by the expression ofhuman ESC markers, karyotypes, methylation states on
promoters of human ESC marker genes, and teratoma for-
mation. WT-iPSCs derived from foreskin fibroblasts [23]
were used as a control group (Additional file 1: Figure S1).
Real-time quantitative PCR
Total mRNA was extracted from iPSCs and differentiated
cells using easy-Blue™ (Intron Biotechnology, Seongnam,
Korea). Briefly, approximately 1 × 105 cells were washed
in phosphate-buffered saline (PBS) and treated with 1 ml
easy-Blue™ solution. After mixing with 200 μl chloroform,
cell lysates were centrifuged and the upper layer of the
supernatants was harvested to isolate RNA. Then, RNA
was precipitated and rehydrated for cDNA synthesis. A
total of 1 μg RNA was annealed with oligo(dT), and cDNA
was synthesized using M-MLV Reverse Transcriptase
(Enzynomics, Daejeon, Korea). The real-time polymerase
chain reaction (RT-PCR) was performed using the follow-
ing cycle conditions: 95 °C denaturation, 60 °C annealing,
and 72 °C elongation. The cycle numbers for each reaction
varied between 30 and 40. Red safe (Intron Biotechnology)
was used for visualization of PCR products in gel electro-
phoresis. For quantitative comparison, the relative expres-
sion level was measured by CFX-Connect real-time
system (Bio-Rad, Hercules, CA, USA). The relative
expression level of each gene was analyzed using a com-
parative threshold cycle method, and the transcription
level of GAPDH was used for normalization. The primers
used in this study are listed in Additional file 2 (Tables S1
and S2).
Bisulfite sequencing
Genomic DNA was isolated from cell samples using a
G-DEX Genomic DNA Extraction Kit (Intron Biotech-
nology). Briefly, 2 × 106 cells were lysed in cell lysis buf-
fer (300 μl) at room temperature for 5 min and then
incubated at 37 °C for 30 min in the presence of RNase
A. After the addition of PPT Buffer (100 μl), cell lysates
were centrifuged at 16,000 × g for 5 min, and the super-
natant was harvested. Isopropanol (300 μl) was added
to the supernatant. After centrifugation at 16,000 × g
for 1 min, the DNA pellet was dissolved in distilled
water (DW). Bisulfite treatment was performed using a
Zymo EZ DNA methylation kit (Zymo Research, Irvine,
CA, USA) according to manufacturer’s instructions.
Briefly, 1 μg of genomic DNA was denatured at 95 °C
for 10 min, and CT-conversion was performed by
addition of the CT Conversion Reagent. CT-converted
DNA was desulfonated in M-Desulfonation Buffer,
washed with M-Wash Buffer, and dissolved in 20 μl of
DW. Bisulfite-treated genomic DNA was amplified by
PCR, individually cloned into a pGEM®-T vector (Pro-
mega, Madison, WI, USA), and sequenced using an ABI
3730XL DNA Analyzer (Applied Biosystems, Foster City,
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the QUMA program (Riken, Kobe, Japan). The primers
used in bisulfate sequencing are listed in Additional file 2
(Table S3).
Immunostaining
The cells were fixed with 4 % formaldehyde for 30 min,
washed twice in PBST (PBS containing 0.1 % Tween 20),
and permeabilized in PBS containing 0.1 % Triton X-100
(Sigma) for 20 min. After blocking with 2 % bovine
serum albumin (BSA; Sigma) for 1 h, the cells were
treated with each primary antibody and incubated at 4 °C
overnight. The primary antibodies used in this study were
as follows: OCT4 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA); SOX2 (Cell Signaling, Danvers, MA, USA);
NANOG (R&D Systems); SSEA4 (Abcam, Cambridge,
England); TRA-1-60 (Millipore, Billerica, MA, USA);
TRA-1-81 (Millipore); NESTIN (Millipore); α-SMA (R&D
Systems); and GATA4 (Santa Cruz Biotechnology). The
cells were washed several times in PBST and incubated
with secondary antibodies (Alexa Fluor 488 or 594; Invi-
trogen) for 1 h. Then, the cells were washed several times
in PBST and counter-stained with 4′-6-diamidino-2-phe-
nylindole (DAPI; Sigma) during the washing step. After
washing with PBST, fluorescence images were observed
on a Zeiss LSM 510 confocal microscope equipped with
argon and helium–neon lasers (Carl Zeiss, Germany).
Teratoma formation of MD-iPSCs
Animal care and experimental procedures were per-
formed under the approval of the Animal Care Commit-
tees of KAIST. MD-iPSCs (1 × 107 cells) were collected
by scraping, mixed with Matrigel (BD Biosciences,
Franklin Lakes, NJ, USA), and subcutaneously injected
into the dorso-lateral area of CAnN.Cg-Foxn1 nu/
CrljOri mice (Orient, Seongnam, Korea). Approximately
2 months after injection, the tumor tissues were dis-
sected and embedded in paraffin wax. Tissue sections
were placed on slide glasses. Hematoxylin and eosin
(H&E; Sigma) staining was performed to observe various
cell types and tissues.
Differentiation of human iPSCs into MSCs
Differentiation of human iPSCs into MSCs was per-
formed as previously described [24, 25]. Briefly, human
iPSC colonies were mechanically dissected and trans-
ferred to low-adhesion petri dishes (SPL Lifesciences,
Pocheon, Korea). Dissected human iPSCs spontaneously
aggregated to form embryoid bodies (EBs) in EB medium
at 37 °C with 5 % CO2 for 1 day. The EB medium consists
of DMEM/F12 supplemented with 10 % Knockout SR, 1
% nonessential amino acids, 1 % penicillin-streptomycin,
and 0.1 mM β-mercaptoethanol. EBs were further cul-
tured in the EB medium containing 10 μM SB431542(Abcam) at 37 °C with 5 % CO2 for 10 days, and then
attached to fibronectin-coated dishes (BD Biosciences).
The attached cells were further cultured in DMEM/F12
supplemented with 1 μM SB431542, 1 % ITS Liquid
media supplement (Sigma), 1 % B27 supplement (Invi-
trogen), and 1 % CD lipid concentrate (Invitrogen) for
4 days. Then, the cells were cultured in α-minimum es-
sential medium (α-MEM; Invitrogen) containing 10 %
FBS for 20 days for MSC induction.
FACS analysis
Cells were dissociated by treatment with trypsin-EDTA
(0.25 %; Invitrogen) for 5 min followed by the addition of
fresh culture medium containing FBS for enzyme inactiva-
tion. After centrifugation at 300 × g for 5 min, the pellets
were resuspended in FACS buffer (PBS containing 2 %
FBS) and filtered through a cell strainer with a 40-μm pore
size (SPL Lifesciences). Dissociated cells were incubated
with specific FACS antibodies against CD44, CD73, CD90,
CD105, and respective isotype controls (Biolegend, San
Diego, CA, USA) at 4 °C for 30 min. After washing with
FACS buffer, samples were analyzed using a FACSCalibur
flow cytometer (BD Biosciences). The positive population
for each antibody was evaluated with FlowJo software
(Tree Star, Ashland, OR, USA). Gating strategy for this
analysis is summarized in Additional file 3 (Figure S2).
Western blotting
Cells were lysed with Pro-Prep protein extraction solution
(Intron Biotechnology) on ice for 1 h. After centrifugation
at 16,000 × g for 30 min, the supernatant was harvested.
The concentration of protein lysates was determined by
Bradford protein assay (Bio-Rad). Proteins were loaded
onto an SDS-PAGE gel (Elpis Biotech, Daejeon, Korea) and
then transferred to a nitrocellulose membrane (Whatman,
Maidstone, England). The membrane was blocked with
TBST (0.1 % Tween in TBS) containing 4 % skim milk,
washed in TBST, and treated with the appropriate primary
antibodies. The primary antibodies used in this study were
as follows: SMAD2 (Cell Signaling); p-SMAD2 (Cell Signal-
ing); ACTIN (Santa Cruz Biotechnology); ATP7A (Hycult
Biotech, Uden, Netherlands); SMAD1 (Cell Signaling); and
p-SMAD1 (Cell Signaling). After washing in TBST, the
membrane was incubated with an horseradish peroxidase
(HRP)-conjugated secondary antibody (Thermo Fisher Sci-
entific, Waltham, MA, USA) at room temperature for 1 h.
The membrane was developed using the ECL system
(Thermo Fischer Scientific), and images were captured by
LAS-3000 (Fuji Film, Tokyo, Japan).
MSC proliferation and apoptosis
Cells were seeded on a gelatin-coated dish at a density
of 2 × 103 cells/cm2 and cultured in α-MEM containing
10 % FBS for 9 days. The number of cells was
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Lauda-Königshofen, Germany). To examine cell viability,
cells were first plated on a gelatin-coated dish at a density
of 2 × 104 cells/cm2 and then cultured for 1 day. After the
addition of the CCK-8 reagents (Dojindo, Kumamoto,
Japan), the cells were incubated at 37 °C for 30 min, and
absorbance was measured at 450 nm. To detect apoptosis,
cells were resuspended in 1X annexin V binding buffer
(eBioscience, San Diego, CA, USA) and incubated with
annexin V-FITC (eBioscience) and propidium iodide (PI;
Sigma) for 15 min in the dark. After FACS analysis,
annexin-positive cells were counted and graphed. For cell
cycle analysis, cells were fixed in cold 70 % ethanol for 1 h
and then treated with RNase A (Sigma) for 30 min. After
treatment with PI for 15 min, the distribution of cells in
the cell cycle was analyzed on a FACSCalibur.
MSC differentiation into OBs and chondrocytes
For osteogenesis, MSCs were seeded on to gelatin-
coated dishes at a density of 2 × 104 cells/cm2 and cul-
tured in α-MEM containing 10 % FBS for 1 day. Then,
MSCs were cultured in StemPro® Osteogenesis Differ-
entiation Medium (Invitrogen) at 37 °C with 5 % CO2
for 21 days. Medium was changed every 3–4 days. Differ-
entiated cells were analyzed by ALP activity, alizarin red S
staining, and Von Kossa staining. For chondrogenesis,
MSCs were concentrated in α-MEM containing 10 % FBS
at a density of 1 × 107 cells/ml. A 10 μl droplet was
placed into noncoated wells of a 96-well plate (SPL
Lifesciences) for 1 h, and 100 μl StemPro® Chondrogenesis
Differentiation Medium (Invitrogen) was added to each
well. The next day, the MSC spheroids that formed were
further cultured in the same medium for 2–3 weeks. The
medium was changed every 3–4 days. The Alcian blue
staining method was utilized to confirm chondrogenic
differentiation.
ALP assay
Fixative solution and ALP staining solution are required
for the ALP assay. Fixative solution is a mixture of 25 ml
citrate solution (Sigma), 65 ml acetone (Junsei Chemical,
Tokyo, Japan) and 8 ml 37 % formaldehyde. To create
the ALP staining solution, 1 ml sodium nitrite solution
(Sigma) was mixed with 1 ml FBV solution (Sigma).
After incubation at room temperature for 2 min, 45 ml
DW and 1 ml naphthol As-BI alkaline solution (Sigma)
were added to the mixture. For the ALP assay, the cells
were fixed in fixative for 30 s and then incubated in ALP
staining solution for 20 min in the dark.
Alizarin red S, Von Kossa, and Alcian blue staining
For alizarin red S staining, the cells were fixed with 10 %
formalin for 20 min and then incubated with alizarin red
S staining solution (Millipore) for 20 min. For Von Kossastaining, cells were fixed with 10 % formalin for 20 min
and then exposed to ultraviolet light in 5 % silver nitrate
(American Master Tech, Lodi, CA, USA) for 1 h. After
washing with DW, the cells were incubated in 5 % sodium
thiosulfate (American Master Tech) at room temperature
for 3 min and then observed under an inverted micro-
scope (Olympus, Tokyo, Japan). For Alcian blue staining,
chondrogenic spheroids were fixed with 10 % formalin for
30 min and embedded in 2 % agarose (LPS solution, Seoul,
Korea) in PBS. Sections of chondrogenic spheroids were
treated with 3 % acetic acid (Millipore) for 3 min and then
incubated in Alcian blue staining solution (American
Master Tech) for 30 min. The stains were detected using
an inverted microscope.
Transfection of ATP7A-siRNA into WT-MSCs
Predesigned siRNAs (Bioneer, Daejeon, Korea) targeting
ATP7A were transfected into WT- MSCs using Lipofec-
tamine® RNAiMAX (Invitrogen). Briefly, a total of 5
pmol siRNA was diluted in 50 μl Opti-MEM® medum
(Invitrogen) and mixed with 3 μl Lipofectamine® RNAi-
MAX diluted in 50 μl Opti-MEM® medum. After 5 min
incubation at room temperature, siRNA-lipid complexes
were added to the culture medium.
Lysyl oxidase activity
To measure lysyl oxidase (LOX) activity, supernatants
were obtained 7 days after the induction of MSCs to
OBs. The LOX assay reaction solution is a mixture of
20 μl Amplite™ HRP substrate stock solution (Abcam),
20 μl HRP (50 U/ml, Abcam), and 5 ml assay buffer
(Abcam). A total of 50 μl supernatant and 50 μl LOX
assay reaction solution were added to 96 wells. After
incubation at 37 °C for 20 min in the dark, fluorescence
was measured at Ex/Em = 540/590 using a microreader
(Tecan, Maennedorf, Switzerland).
Matrix collagen assay
To measure collagen deposition in the extracellular
matrix (ECM), human iPSC-derived OBs were fixed in
200 μl Kahle fixative solution (Chondrex, Redmond,
WA, USA) in four-well dishes for 10 min. After washing
with DW, the cells were incubated in 200 μl dye solution
(Chondrex) at room temperature for 30 min. After
removal of the dye solution, 500 μl dye extraction buffer
(Chondrex) was added to elute the bound dye solution.
The OD values of the eluted dye solution were measured
at 540 nm and 605 nm using a microreader.
Measurement of intracellular copper concentration
WT-MSCs and MD-MSCs were detached with trypsin-
EDTA and digested in a mixture of 2 ml 65 % HNO3
(J.T. Baker®, PA, USA), and 7 ml deionized water. Pre-
pared samples were further digested in the Microwave
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150 °C. Then, copper concentration was analyzed by
inductively coupled plasma (ICP) mass spectrometry
(Agilent Technologies, CA, USA).
Statistical analysis
The statistical significance of the real-time RT-PCR
data and other assays was evaluated by Student’s t-test,
and p < 0.05 was considered significant.
Results
Generation of iPSCs from MD patient fibroblasts
Dermal fibroblasts were obtained from two different
patients who each had a mutation in the ATP7A gene
[26]. The 2-year-old Patient 1 (Menkes disease case 1,
MD1) had an intronic mutation (c.4005 + 5G > A) that
causes a splicing error on exon 20. The newborn Patient
2 (Menkes disease case 2, MD2) had a large genomic
deletion (c.121-930_2626 + 488del) encompassing the
exon 3–12 region (Table 1). The mutated region of
patient MD1 is in the ATP-binding domain, which modu-
lates the catalytic activity, and the deleted regions of MD2
include five copper-binding domains, four transmembrane
regions, and fragments of a phosphatase domain that
disturb a large portion of ATP7A (Additional file 4:
Figure S3A). The two patients showed typical symp-
toms of MD, including severe neurodegeneration and
intensive connective tissue abnormality (Table 1).
MD-iPSCs were generated from dermal fibroblasts of
patients MD1 and MD2 by ectopic expression of
OCT4, SOX2, cMYC, and KLF4. A MD1-iPSC clone, a
MD2-iPSC clone, and WT-iPSCs were used in this
study. MD1- and MD2-iPSCs had a typical morphology
with tightly packed clusters and sharp boundaries and
expressed pluripotency-associated marker genes (Fig. 1aTable 1 Genetic information of Menkes patients
Identification number MD Case1 (MD1)
Gender Male
Age at diagnosis 4 months
Genotype c.4005 + 5G > A of ATP7A (Splic
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Current outcomes Death (4.7 years)and Additional file 4: Figure S3B). Exogenous genes
were silenced after iPSC generation (Fig. 1b). MD1- and
MD2-iPSCs differentiated into various cell types of the
three germ layers in vitro (Additional file 4: Figure S3C)
and formed teratomas after subcutaneous injection into
nude mice (Fig. 1c). Furthermore, methylation of CpG
dinucleotides in the promoter of OCT4, NANOG, REX1
genes were highly demethylated in MD1- and MD2-
iPSCs compared with each patient’s fibroblasts (Fig. 1d),
indicating successful epigenetic reprogramming. MD1-
iPSCs had a normal karyotype, and MD2-iPSCs showed
a polymorphic variant (pericentric inversion of chromo-
some 9) that was the same as the karyotype of the MD2
patient (Additional file 4: Figure S3D). Mutations of the
ATP7A gene were confirmed again at the genomic and
transcriptional levels in MD1- and MD2-iPSCs (Additional
file 4: Figure S3E and S3F).
Differentiation of MD-iPSCs into MSCs
MSCs were differentiated from MD-iPSCs using an EB-
based method (Fig. 2a). In this method, EBs were treated
with an inhibitor of transforming growth factor-beta sig-
naling, SB431542 (SB), to enhance differentiation into car-
diac mesoderm and neuro-ectoderm lineages. Treatment
with SB efficiently blocked SMAD2 phosphorylation in all
WT, MD1 and MD2 EBs (Additional file 5: Figure S4A).
SB-treated EBs were morphologically normal in the
three groups (Fig. 2b), and showed upregulated expression
of a cardiac mesodermal gene, cTNT, and a neuro-
ectodermal gene, NEUROD1, compared to undifferenti-
ated cells (Additional file 5: Figure S4B). After attachment
of SB-treated EBs to fibronectin-coated dishes, develop-
ment of mesenchymal cells appeared to be retarded in
MD-iPSCs (MD1- and MD2-iPSCs) compared with that
of WT-iPSCs. Mesenchymal morphology could beMD case2 (MD2)
Male
36 days
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Fig. 1 Generation of MD-iPSCs. a Expression of pluripotent markers in MD-iPSCs. MD1- and MD2-iPSCs had normal morphologies and expressed
pluripotent markers. Scale bars = 500 μm. b Transcriptional expression of transgenes such as OCT4, SOX2, cMYC, and KLF4 in MD-Fib, MD-inf,
and MD-iPSCs. Transcription of the transgenes was detected only in infected MD1 and MD2 fibroblasts. c Teratoma formation of MD-iPSCs in
immunodeficient mice. H&E staining was performed to detect diverse cell types and tissues (neural rosette, ectoderm; adipose tissue,
mesoderm; and secretory gland, endoderm). Scale bars = 100 μm. d Epigenetic reprogramming in MD-iPSCs. Promoters of pluripotent genes
were highly demethylated in MD1- and MD2-iPSCs compared with fibroblasts. Each circle represents the methylation status of single CpG
dinucleotides: empty circle, unmethylated; filled circle, methylated. ALP alkaline phosphatase, iPSC induced pluripotent stem cell, Inf infected
fibroblasts, Fib normal fibroblasts, MD1/2 Menkes disease patient 1/2, Tg transgene
Kim et al. Stem Cell Research & Therapy  (2015) 6:160 Page 6 of 12observed at 1 week after α-MEM induction in the WT-
iPSC group, whereas mesenchymal morphology was ob-
served at 2 weeks in the MD1- and MD2-iPSC groups
(Fig. 2c). Differences in mesenchymal development be-
tween the WT- and MD-iPSC groups were also apparent
after FACS analysis (Fig. 2d). CD105 expression in the
MD1- and MD2-iPSC groups was relatively low by 3
weeks during mesenchymal development compared with
the WT-iPSC group. The MD1- and MD2-iPSC groups
also showed a slight reduction in CD90 expression after
1 week of α-MEM induction, but no difference was
detected in the expression of other MSC markers, such
as CD44 and CD73, between the WT- and MD-iPSC
groups. These results demonstrate that the induction of
MD-EBs towards the mesenchyme may be delayed in
the early stage. Intriguingly, however, MD1- and MD2-
MSCs achieved the normal MSC morphology and cell
density of WT-MSCs after a long-term culture of 5
weeks (Fig. 3a). Furthermore, the expression level ofCD105 in MD-MSCs was similar to that of WT-MSCs
(Fig. 3b), indicating the complete maturation of MSCs.
In addition, mature MD-MSCs had normal cellular
functions, including cell growth (Fig. 3c), viability
(Fig. 3d), apoptosis (Fig. 3e) and cell cycle (Fig. 3f )
compared with WT-MSCs. Thus, ATP7A mutations did
not influence fundamental cellular functions in MSCs.
Genetic mutations of the ATP7A gene were confirmed
again in the MD1- and MD2-MSCs (Additional file 6:
Figure S5A and S5B, respectively). The ATP7A protein
was not detected in either the MD1- or MD2-MSCs
(Additional file 6: Figure S5C), and MD-MSCs exhib-
ited higher levels of intracellular copper than WT-
MSCs (Additional file 2: Table S4).
Impaired osteogenesis of MD-MSCs
To test the effect of ATP7A mutations on osteogenesis
during bone formation, MD-MSCs were differentiated
into OBs. To monitor OB differentiation, an ALP assay,
Fig. 2 Differentiation of MD-iPSCs into MSCs. a Schematic protocol for differentiation of MD-iPSCs into MSCs. b Formation of embryoid bodies
(EBs) from MD-iPSCs. MD1- and MD2-iPSCs formed EBs with typical morphologies. Scale bars = 500 μm. c Representative images of iPSC-derived
cells at 0, 1, 2, and 3 weeks after α-MEM induction. Retardation of MSC differentiation was observed both in the MD1- and MD2-iPSC groups
compared with the WT-iPSC group. Scale bars = 500 μm. d Expression of MSC markers in MD-MSCs. MD1- and MD2-MSCs showed lower
expression of CD105 compared with WT-MSCs. Gating strategy for this analysis is summarized in Additional file 3 (Figure S2). α-MEM α-minimum essential
medium, D day of differentiation, DMEM Dulbecco’s modified Eagle’s medium, FBS fetal bovine serum, ITS ITS liquid media supplement, MD1/2 Menkes
disease patient 1/2, SB SB431542, SR Knockout Serum Replacement, wk weeks, WT wild type
Kim et al. Stem Cell Research & Therapy  (2015) 6:160 Page 7 of 12alizarin red S staining, and Von Kossa staining were per-
formed. In WT-MSCs, ALP activity was clearly observed
at 7 days and reached the highest level 14 days after OB
induction (Fig. 4a, upper panel). Intriguingly, ALP activ-
ity was barely detected at 7 days and was very weak even
at 21 days in the MD1-MSCs during OB differentiation
(Fig. 4a, middle panel). MD2-MSCs also showed low
ALP activity in the process of OB differentiation (Fig. 4a,bottom panel). Thus, we found that MD-MSCs had
aberrant ALP activity during OB differentiation. ALP
activity is very important for calcium crystallization or
mineralization during bone formation [27]. Therefore,
we speculated that low ALP activity might lead to abnor-
mal calcium deposition in MD-MSCs. As expected,
MD1- and MD2-MSCs showed lower levels of calcium
deposition during OB differentiation compared with
Fig. 3 Maturation of MD-MSCs by extended culture. a Bright-field microscopy images of MD-MSCs. MD1- and MD2-MSCs were matured by
long-term culture for 5 weeks. Scale bars = 500 μm. b Expression of MSC surface antigen markers. After long-term culture, CD105-positive cells
were increased in MD1- and MD2-MSCs. Gating strategy for this analysis is summarized in Additional file 3 (Figure S2). c Growth curves of WT- and
MD-MSCs. Each symbol indicates the number of cells at each day of culture. The data are presented as the mean ± SE (n = 4). d Viability of WT- and
MD-MSCs. Absorbance data of MD-MSCs obtained from a viability assay (see the Materials and Methods section) are expressed as relative to
the WT-MSCs. The data are presented as the mean ± SE (n = 3). e Apoptosis of WT- and MD-MSCs. The percentage of early apoptotic cells
(annexin+ and PI−) and late apoptotic cells (annexin+ and PI+) of WT- and MD-MSCs are depicted on a graph. The data are presented as the
mean ± SE (n = 2). f Cell cycle analysis of WT- and MD-MSCs. Cell cycle distributions of WT- and MD-MSCs were determined by FACS analysis.
The percentage of cells in each phase of the cell cycle (G1, S, and G2/M) was quantified and depicted as a graph. The data are presented as
the mean ± SE (n = 2). MD1/2 Menkes disease patient 1/2, MSC mesenchymal stem cell, PI propidium iodide, wk weeks, WT wild type
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reduced ALP activity accounts for insufficient calcium
crystallization or mineralization. Relative expression of
the matrix-related genes OPN and OCN was significantly
downregulated, whereas the expression of the osteogenic
transcription factor RUNX2 was similar in MD-OBs
compared with WT-OBs (Fig. 4d). To test whether
ATP7A is associated with osteogenesis, a knockdownexperiment using siRNA targeting ATP7A was carried out
in WT-MSCs. In a preliminary experiment, siRNA use effi-
ciently downregulated ATP7A transcript (Additional file 7:
Figure S6). Knockdown of ATP7A in WT-MSCs
also showed impaired osteogenesis with downregula-
tion of osteogenic genes (Fig. 4e and f ). Thus,
knockdown of ATP7A in WT-MSCs recapitulated
osteogenic impairments of MD-MSCs. Our results
Fig. 4 Impaired osteogenesis in MD-MSCs. a Representative images of ALP activity in WT- and MD-MSCs during OB differentiation. ALP activity
was observed as red granules. D, days after osteogenesis induction. b Representative images of alizarin red S staining in WT- and MD-MSCs during
OB differentiation. Alizarin red S staining presented as red granules. c Representative images of Von Kossa staining in WT- and MD-MSCs during
OB differentiation. Von Kossa staining was observed as black dots. Scale bars = 500 μm. d Relative expression of osteogenic genes RUNX2, OPN,
and OCN in MD-MSCs during osteogenesis. The data are presented as the mean ± SE (n = 3). e, f Effects of ATP7A knock-down on osteogenesis
in WT-MSCs. e Representative images of ALP activity, alizarin red S staining, and Von Kossa staining after transfection of siRNAs targeting ATP7A
gene. Scramble siRNA (si-SCR) was also transfected in WT-MSCs as a control. f Relative expression of RUNX2, OPN, and OCN after ATP7A knockdown.
The data are represented as the mean ± SE (n = 3). *p < 0.05, **p < 0.01. ALP alkaline phosphatase, D day of differentiation, MD1/2 Menkes disease
patient 1/2, WT wild type
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formation.
Previous findings have shown that bone morpho-
genetic protein 2 (BMP2) induces OB differentiation of
MSCs [28, 29]. We therefore examined whether impaired
osteogenesis in MD-MSCs is caused by insufficient activa-
tion of the BMP2 signaling pathway. No differenceswere detected in the activity of p-SMAD1 between the
WT- and MD-MSCs (Additional file 8: Figure S7A). In
addition, chondrogenesis appeared normal in MD-
MSCs (Additional file 8: Figure S7B). These results sug-
gest that decrements of ALP activity and mineralization
adversely affect osteogenesis in MD-MSCs. Next, activ-
ity of LOX, a copper-dependent enzyme, was measured
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MD1- and MD2-OBs showed lower LOX activity than
WT-OBs (Additional file 9: Figure S8A), but the amount
of matrix collagen was not different between WT- and
MD-OBs (Additional file 9: Figure S8B). Therefore, it is
conceivable that impaired mineralization is not due to
reduced deposition of collagen in MD-MSCs. Taken
together, we suggest that the ATP7A mutation causes
decreased ALP activity and mineralization, eventually
resulting in impaired osteogenesis in MD.
Discussion
Here, we provide novel insight into the impaired
osteogenesis in MD using iPSCs. ATP7A, which is a
major copper transporter, plays important roles in
copper absorption and delivery of copper to the hu-
man body [6, 8]. Copper is one of the essential trace
elements in normal development, and its homeostasis
should be tightly regulated [30]. Disability of copper
utilization in MD patients who have a defective ATP7A
gene causes severe multisystemic phenotypes such as con-
nective tissue abnormalities. In this study, MD-iPSCs with
ATP7A mutations showed retardation of MSC develop-
ment (Fig. 2d), although MD-MSCs matured after ex-
tended culturing in vitro (Fig. 3). Subsequently, several
osteogenic defects, including decreased ALP activity and
weak calcium mineralization, were observed in MD-MSCs
and ATP7A-knockdown WT-MSCs during OB differenti-
ation (Fig. 4).
ALP activity appears to be associated with calcium de-
position during osteogenesis. During osteogenesis, ALP
produces inorganic phosphate (Pi) from pyrophosphate
(PPi), and controls the balance between Pi and PPi levels
in the ECM [31, 32]. Pi is further crystallized with cal-
cium and accelerates calcium mineralization in the
ECM. Dysfunction of the ALP gene causes a genetic dis-
order called hypophosphatasia, which is characterized by
abnormal bone formation [27]. Here, low activity of ALP
resulted in decreased calcium mineralization in MD-
MSCs during OB differentiation as shown by alizarin red
S and Von Kossa staining (Fig. 4).
LOX mediates cross-linking of collagen and elastin in
the ECM, which enhance tensile strength and structural
integrity of connective tissues [3]. It has been postulated
that decreased LOX activity accounts for the impaired
connective tissue in MD patients [33, 34]. Reduced
activity of LOX is also implicated in abnormal vascu-
lopathy such as the vascular tortuosity and peripheral
aneurysms in MD and its allelic variant, occipital horn
syndrome (OHS) [35]. Aberrant internal elastic lamina
structure is observed in the MD patient and the
Menkes mouse model [36]. Cultured fibroblasts of MD
and OHS show abnormalities in the expression of con-
nective tissue genes [37]. Furthermore, bladder diverticula,inguinal hernia, skin laxity, hyperelasticity, and occipital
exostosis are caused by reduced LOX activity [38].
In this study, LOX activity was decreased in MD-MSCs
during OB differentiation. Nonetheless, there were no
changes in collagen deposition in this study. These results
raise the possibility that another role of LOX might be
involvement in the aberrant OB differentiation in MD-
MSCs. In fact, it has been reported that LOX activity is
involved in many biological functions other than collagen
cross-linking, such as metastasis, tumor cell growth, cell
migration and motility, angiogenesis, cell signaling, and
transcription [39–42]. Thus, the identification of a new
role for LOX in MD-MSCs during OB differentiation
would be very interesting.
Taken together, these data show that utilization of
intracellular copper is unavailable in MD cells due to
dysfunctional ATP7A. This study provides additional
insight into the pathophysiology of bone defects caused
by the ATP7A mutation in MD.
Conclusions
Here we described the important role of ATP7A and cop-
per during osteogenesis using MD-derived iPSCs. During
OB differentiation, several osteogenic impairments such
as low ALP activity, reduced calcium mineralization and
decreased expression of osteogenic marker genes were ob-
served. Knockdown of ATP7A in WT-MSCs recapitulated
the impaired osteogenesis observed in MD-MSCs. Our
results provide new insight into the important role of
ATP7A in bone formation.
Additional files
Additional file 1: Figure S1. Characterization of WT-iPSCs. (A) Expression
of pluripotent markers in WT-iPSCs. (B) Teratoma formation of MD-iPSCs in
immunodeficient mice. (C) Epigenetic reprogramming in WT-iPSCs.
(TIFF 2486 kb)
Additional file 2: Table S1. Primers used in RT-PCR analysis. Table S2
Primers used in ATP7A genotyping of MD-derived cells. Table S3 Primers
used in methylation analysis. Table S4 Copper concentration in WT- and
MD-MSCs. (DOCX 19 kb)
Additional file 3: Figure S2. Detailed gating strategy for each MSC
surface antigens. Gating strategy for CD44 surface antigen shown as a
representative. Live cells (gate A) were gated based on forward scatter
and side scatter. Staining with isotype control (PE-conjugated) was used
to exclude CD44-negative events. This gate was then applied to samples
stained with anti-CD44 antibody (PE-conjugated) to identify CD44 positive
events. In merged image, red line indicates isotype control and black tinted
area indicates CD44 positive events. (TIFF 1455 kb)
Additional file 4: Figure S3. Characterization of MD-iPSCs. (A) Schematic
defective regions of ATP7A in MD1 and MD2 patients. The functional
domains of ATP7A are depicted. ATP7A has six copper-binding domains,
one phosphatase domain, one phosphorylation domain, one ATP-binding
domain, and eight transmembrane domains. The defective regions of each
patient are marked as boxes. (B) Transcriptional expression of pluripotent
genes in MD-fibroblasts and MD-iPSCs. GAPDH was used as a control. (C) In
vitro differentiation of MD-iPSCs. Immunostaining of NESTIN (ectoderm, red),
α-SMA (mesoderm, green), and GATA4 (endoderm, green) was performed 7
days after spontaneous EB differentiation. DAPI showed nuclear counterstaining
Kim et al. Stem Cell Research & Therapy  (2015) 6:160 Page 11 of 12(blue). Scale bar = 500 μm. (D) Karyotypes of MD1- and MD2-iPSCs. (E) Genetic
mutations in MD1-fibroblasts and MD1-iPSCs. A single-base substitution was
confirmed in MD1-fibroblasts and MD1-iPSCs (Figure E-a). The resultant PCR
products were different in MD1-fibroblasts and MD1-iPSCs (Figure E-b). The size
difference (450 bp in WT and 246 bp in MD1) generated by exon skipping
was analyzed by gel electrophoresis. (F) Mutations in MD2-fibroblasts and
MD2-iPSCs. Strategy for duplex PCR was explained as an illustration
(Figure F-a). Size differences (532 bp in WT and 224 bp in MD2)
generated by a large genomic deletion between WT- and MD2-fibroblasts
were detected (Figure F-b). The primers used in this study are listed in
Additional file 1 (Table S2). (TIFF 4321 kb)
Additional file 5: Figure S4. Characterization of EBs during MSC
differentiation. (A) SMAD2 phosphorylation in WT- and MD-EBs during
MSC differentiation. SB treatment suppressed p-SMAD2 in WT- and MD-EBs.
(B) Relative expression of neuro-ectoderm and cardiac mesoderm marker
genes (NEUROD1 and cTNT, respectively) in WT- and MD-EBs. The data are
presented as the mean ± SE (n = 3); *p < 0.05, **p < 0.01. (TIFF 2052 kb)
Additional file 6: Figure S5. Confirmation of MD-MSCs. (A) Genetic
mutation of the ATP7A gene in MD1-MSCs. A single-base substitution was
confirmed again in MD1-MSCs. (B) Genetic mutation of the ATP7A gene
in MD2-MSCs. Size differences in the PCR product were observed in
MD2-MSCs. (C) Expression of ATP7A in WT- and MD-MSCs. ATP7A protein
was not detected in MD1- and MD2-MSCs. (TIFF 936 kb)
Additional file 7: Figure S6. Relative expression of ATP7A after siRNA
transfection. The data are represented as the mean ± SE (n = 3); **p < 0.01.
(TIFF 326 kb)
Additional file 8: Figure S7. Osteogenesis and chondrogenesis from
MSCs. (A) SMAD1 phosphorylation in WT- and MD-MSCs during osteogenesis.
(B) Differentiation of WT- and MD-MSCs into chondrocytes. WT- and MD-MSCs
differentiated into chondrocytes following the procedures described in the
Materials and Methods section. Morphologies of chondrocyte spheroids were
similar between WT- and MD-MSCs (upper panel). Scale bar = 500 μm.
Additionally, MD-MSCs stained normally with Alcian blue solution
(lower panel). Scale bar = 50 μm. (TIFF 1998 kb)
Additional file 9: Figure S8. Activity of LOX and matrix collagen in
WT- and MD-OBs. (A) LOX activity in WT- and MD-OBs. Fluorescence
data showing the LOX activity of MD-OBs (see the Materials and
Methods section) are expressed as values relative to those of WT-OBs.
The data are presented as the mean ± SE (n = 3); *p < 0.05, **p < 0.01.
(B) Relative amount of matrix collagen in WT- and MD-OBs. The absorbance
data obtained from a matrix collagen assay (see the Materials and Methods
section) are expressed as values relative to that of WT-OBs. The data are
presented as the mean ± SE (n = 3). (TIFF 813 kb)
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